Tune Therapeutics

Don’t miss Tune’s Director of Delivery Science Tyler Goodwin, Ph.D., in this deep-dive on accelerating mRNA-LNP development, hosted by Advancing RNA #rna #lnp #epigenetics #tunetx

I recently came across Dr. Mehmood Khan`s opening speech at the Hevolution Foundation Global Healthspan Summit 2025, and one statement truly resonated with me: "𝘔𝘰𝘴𝘵 𝘱𝘦𝘰𝘱𝘭𝘦 𝘢𝘳𝘰𝘶𝘯𝘥 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥 𝘢𝘤𝘵𝘶𝘢𝘭𝘭𝘺 𝘥𝘰𝘯`𝘵 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘭𝘪𝘷𝘦 𝘭𝘰𝘯𝘨𝘦𝘳 𝘫𝘶𝘴𝘵 𝘧𝘰𝘳 𝘴𝘢𝘬𝘦 𝘰𝘧 𝘭𝘪𝘷𝘪𝘯𝘨 𝘭𝘰𝘯𝘨𝘦𝘳. 𝘛𝘩𝘦𝘺 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘣𝘦 𝘪𝘯𝘥𝘦𝘱𝘦𝘯𝘥𝘦𝘯𝘵. 𝘛𝘩𝘦𝘺 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘣𝘦 𝘧𝘶𝘯𝘤𝘵𝘪𝘰𝘯𝘢𝘭, 𝘮𝘦𝘯𝘵𝘢𝘭𝘭𝘺 𝘢𝘯𝘥 𝘱𝘩𝘺𝘴𝘪𝘤𝘢𝘭𝘭𝘺. 𝘛𝘩𝘦𝘺 𝘸𝘢𝘯𝘵 𝘮𝘰𝘣𝘪𝘭𝘪𝘵𝘺. 𝘛𝘩𝘦𝘺 𝘥𝘰 𝘯𝘰𝘵 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘥𝘦𝘱𝘦𝘯𝘥 𝘪𝘯 𝘢𝘯𝘺 𝘸𝘢𝘺 𝘰𝘯 𝘵𝘩𝘦𝘪𝘳 𝘭𝘰𝘷𝘦𝘥 𝘰𝘯𝘦𝘴... 𝘞𝘩𝘢𝘵 𝘪𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘵𝘰 𝘩𝘶𝘮𝘢𝘯𝘪𝘵𝘺 𝘪𝘴 𝘩𝘦𝘢𝘭𝘵𝘩𝘴𝘱𝘢𝘯." (not lifespan) Dr. Khan emphasized that we stand at a crossroads where the narrative must evolve from merely extending life as patients to truly enhancing life as consumers. This is a critical point, especially as the 𝗻𝘂𝗺𝗯𝗲𝗿 𝗼𝗳 𝗶𝗻𝗱𝗶𝘃𝗶𝗱𝘂𝗮𝗹𝘀 𝗼𝘃𝗲𝗿 𝟲𝟬 𝗶𝘀 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝗲𝗱 𝘁𝗼 𝗱𝗼𝘂𝗯𝗹𝗲 𝗯𝘆 𝟮𝟬𝟱𝟬. "𝘐𝘧 𝘺𝘰𝘶 𝘱𝘳𝘰𝘫𝘦𝘤𝘵 𝘵𝘩𝘢𝘵 𝘪𝘯𝘵𝘰 𝘵𝘩𝘦 𝘧𝘶𝘵𝘶𝘳𝘦, 𝘰𝘷𝘦𝘳 𝘵𝘩𝘦 𝘯𝘦𝘹𝘵 20-30 𝘺𝘦𝘢𝘳𝘴, 𝘸𝘦 𝘸𝘪𝘭𝘭 𝘩𝘢𝘷𝘦 𝘢 𝘩𝘶𝘨𝘦 𝘮𝘪𝘴𝘮𝘢𝘵𝘤𝘩 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 𝘵𝘩𝘰𝘴𝘦 𝘸𝘩𝘰 𝘢𝘳𝘦 𝘩𝘦𝘢𝘭𝘵𝘩𝘺 𝘢𝘯𝘥 𝘢𝘣𝘭𝘦 𝘵𝘰 𝘤𝘰𝘯𝘵𝘳𝘪𝘣𝘶𝘵𝘦 𝘢𝘤𝘵𝘪𝘷𝘦𝘭𝘺 𝘢𝘯𝘥 𝘵𝘩𝘰𝘴𝘦 𝘸𝘩𝘰 𝘢𝘳𝘦 𝘳𝘦𝘤𝘪𝘱𝘪𝘦𝘯𝘵𝘴. 𝘛𝘩𝘢𝘵’𝘴 𝘪𝘧 𝘸𝘦 𝘥𝘰𝘯’𝘵 𝘥𝘰 𝘴𝘰𝘮𝘦𝘵𝘩𝘪𝘯𝘨 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵. 𝘖𝘶𝘳 𝘨𝘰𝘢𝘭 𝘪𝘴 𝘵𝘰 𝘤𝘩𝘢𝘯𝘨𝘦 𝘵𝘩𝘢𝘵 𝘧𝘶𝘵𝘶𝘳𝘦.” Hevolution Foundation isn't just a fund - it's a catalyst for healthspan research. With $400 million invested in longevity science over the past three years, it's driving innovation and healthspan extension. 👇 Want to know who Hevolution Foundation is backing? 👇 Vandria SA is developing first-in-class small molecule mitophagy inducers. Their lead compound VNA-318 aims to combat neurodegenerative diseases such as Alzheimer’s and Parkinson’s - ($30.7 𝘔, 𝘚𝘦𝘳𝘪𝘦𝘴 𝘈). Tune Therapeutics is focused on Tune-401, a promising epigenetic silencing drug specifically designed to target the virus responsible for chronic Hepatitis B - ($175 𝘔, 𝘚𝘦𝘳𝘪𝘦𝘴 𝘉). Rubedo Life Sciences uses its drug discovery platform to engineer novel first-in-class small molecules which selectively target various types of senescent cells. Their lead candidate RLS-1496 is a first-in-class GPX4 modulator addressing chronic skin conditions like atopic dermatitis and psoriasis - ($40 𝘔, 𝘚𝘦𝘳𝘪𝘦𝘴 𝘈). Aeovian Pharmaceuticals is working on AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor aimed at treating epilepsy associated with tuberous sclerosis complex (TSC) - ($50 𝘔, 𝘚𝘦𝘳𝘪𝘦𝘴 𝘈). #Healthspan #Longevity #Aging Included VC 💛 💙 💚

Accelerating mRNA-LNP 🧬Development: A Deep Dive Into Analytical & Manufacturing Technology Innovation Join this expert panel in a deep dive discussion that will home in on mRNA-LNP Development and the limitations of current analytical and manufacturing technologies, and where innovations need to be seen in terms of analytical technologies, PAT, automation, single-use, continuous manufacturing, decentralized manufacturing, and more. Reserve your spot: https://lnkd.in/epPVffjU 📅 Thursday, March 13, 2025 | 2:00 PM EDT 🎙️ Expert Panel: ✅ Heidi Zhang, EVP & Head of Technical Operations, Tune Therapeutics ✅ Zoltán Kis, Senior Lecturer, Department of Chemical and Biological Engineering, The University of Sheffield ✅ Anna Rose Welch, Editorial & Community Director, Advancing RNA #mrna #lnp #rna

Earlier this month, Tune CSO Derek Jantz spoke to Longevity Technology / News on the transformative potential of gene tuning in the regenerative medicine space. Catch his insights here:

Going to TIDES USA next month ? Then don’t miss our Head of Gene Delivery Tyler Goodwin, Ph.D., who will be offering fresh insights on developments in vector technology for in vivo gene therapeutics. Details below.

It was an honor to be on this panel with these great scientists and to share our thoughts on epi editing!

TuneTX President, Co-Founder and CFO Akira Matsuno will be attending the Global Healthspan Summit in Riyadh this week, speaking on the growing power and potential of epigenome editing in the cell and regenerative medicine space. Link to livestream provided below, for those not lucky enough to attend in person.

An honorable mention for Tune in Clinical Research News, among biotechs securing new funding this month: https://lnkd.in/e5Ez7sFm

Check out this short (but enlightening) interview for Bioprocess Online, in which Tune CSO Derek Jantz offers his outlook on current developments and recent milestones in genetic medicine. Including the growing contributions of: ➡️ Epigenome editing – a precise approach to controlling gene expression without altering DNA sequences ➡️ Single-cell multi-omics – delivering deeper insights into cell populations, one cell at a time ➡️ LNP mRNA technology – expanding its potential and moving toward more affordable mRNA drug products View the full interview here: https://bit.ly/4gk2CTE #GeneTherapy #EpigenomeEditing #BiotechInnovation #LNP #mRNA #PrecisionMedicine

A solid summary by GeneOnline: Cell & Gene Therapies Take Center Stage at JPM 2025 “Tune’s innovative approach to gene silencing holds promise for treating chronic conditions and reshaping the landscape of regenerative medicine.”